NCT03229759已完成2 期
A Randomized Single Center Blinded Clinical Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth Compared to Vehicle and 0.9% Saline
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 1
- 主要终点
- Bacterial Count at 10 Minutes Post Application
研究概览
简要总结
Healthy volunteers will receive treatment to two body locations with the investigational product and placebo and the antimicrobial effectiveness of each treatment will be measured.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and/or females, at least 18 years or older and of any race.
- •Are in good general health.
- •Unable to become pregnant, or willing to use an acceptable method of contraception (i.e. oral contraception, intra-uterine device [IUD], diaphragm, condom, abstinence, bilateral Tubal ligation, or are in a monogamous relationship with a partner who has had a Vasectomy) to prevent pregnancy for at least 14 days immediately preceding Treatment Day and throughout the duration of the study, if female of child-bearing potential.
- •All female subjects must have a negative urine pregnancy test on Treatment Day prior to any applications of the study products.
- •Have skin within 6 inches of the test sites that is free of dermatoses, abrasions, cuts, lesions or other skin disorders.
- •Cooperative and willing to follow Subject Instructions
- •Cooperative and willing to sign Consent Form and HIPAA Authorization Form.
- •Able to read, write and follow instructions in English.
排除标准
- •Exposure to topical or systemic antimicrobials or any other product known to affect the normal microbial flora of the skin, antibiotics or steroids (other than hormones for contraception or post-menopausal reasons) exposure within 14 days prior to Treatment Day and for the remainder of the study. Restrictions include, but are not limited to antimicrobial-containing soaps, antiperspirants/deodorants, shampoos, lotions, perfumes, after shaves, and colognes.
- •Swimming in chemically treated pools or bathing in hot tubs, spas and whirlpools within 14 days prior to Treatment Day and for the remainder of the study.
- •Use of tanning beds, hot waxes, or depilatories, including shaving (in the applicable test areas) within 14 days prior to Treatment Day and for the remainder of the study.
- •Contact with strong detergents, solvents, acids, bases, bug repellant, fabric softener-treated clothing, UV treated clothing or other household chemicals in the applicable test areas within 14 days of the Treatment Day and for the remainder of the study.
- •Subjects who have a history of sensitivity to vinyl, natural rubber latex, adhesive skin products (e.g., Band-Aids, medical tapes), polyester, metals, inks, common antibacterial agents found in common personal beauty or personal care soaps, lotions, or ointments
- •Subjects who have asthma requiring medication, diabetes, hepatitis B or C, an organ transplant, mitral valve prolapse with a heart murmur, congenital heart disease, lupus, Crohn's disease, medicated multiple sclerosis, internal prosthesis or any immunocompromised conditions (such as AIDS or HIV positive).
- •Subjects who have a history of skin allergies.
- •Subjects who have a history of skin cancer within 6 inches of the applicable test areas or have received treatment for any type of internal cancer within the 5 years prior to enrollment.
- •Any tattoos or scars on the test sites or within 2 inches of the test sites; skin blemishes or warts may be permissible with the specific approval of the Principal Investigator or consulting physician.
- •Dermatoses, cuts, lesions, active skin rashes, scabs, breaks in the skin or other skin disorders within 6 inches on or around the test sites.
- •A currently active skin disease or inflammatory skin condition (for example contact dermatitis; psoriasis, and eczema) anywhere on the body.
- •Subjects who are pregnant, attempting pregnancy, or nursing.
- •Subjects who have showered or bathed within at least 72 hours of the Treatment Day (sponge baths may be taken, however, the lower abdomen and upper thigh region must be avoided).
- •Subjects who receive an irritation score of 1 (any redness, swelling, rash, or dryness present at any treatment area) for any individual skin condition prior to the Treatment Day baseline sample collection.
- •Participation in another clinical trial in the 30 days prior to signing the informed consent for this study, current enrollment in another clinical trial, or have already participated in this study.
研究组 & 干预措施
Investigational Product
Experimental
Polyester cloth impregnated with investigational product
干预措施: Octenidine Dihydrocloride in aqueous solution (Drug)
Vehicle Control (VC)
Placebo Comparator
Polyester cloth impregnated with the vehicle control
干预措施: Vehicle Control (Other)
Saline Control (SC)
Placebo Comparator
Saline applied wtih polyester cloth
干预措施: Saline Control (Other)
结局指标
主要结局
Bacterial Count at 10 Minutes Post Application
时间窗: 10 minutes after application of test product
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of XL784 in Patients With Albuminuria Due to Diabetic NephropathyAlbuminuriaDiabetic NephropathyNCT00312780Symphony Evolution, Inc.125
已完成
2 期
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaNeoplasm MetastasisMelanomaNCT00055562Celgene Corporation274
Unknown
不适用
Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Cellulite of the Buttocks and ThighsCelluliteNCT04830722Goldman, Butterwick, Fitzpatrick and Groff20
已完成
不适用
MANTA/TRIAL, Randomized Clinical Trial of Laparoscopic Toupet versus 180˚ Anterior Fundoplication for Gastroesophageal Reflux Diseasegastroesophageal reflux disease, fundoplication, laparoscopic surgeryNL-OMON28375St Antonius Hospital, Nieuwegein94
进行中（未招募）
3 期
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerStage III Pancreatic CancerNCT03899636Angiodynamics, Inc.528